EPAT PLAYS A KEY ROLE IN WORKING TOWARDS DISCOVERING INNOVATIVE BREAKTHROUGHS BY COMBINING OUR BIOLOGICS-BASED PRECISION MEDICINES WITH EISAI’S VAST KNOWLEDGE OF CHEMICALS AND GENETICS.
That’s the goal at Epochal Precision Anti-Cancer Therapeutics (EPAT), our Biologics Discovery Center located in Exton, Pennsylvania. EPAT is developing precision oncology therapies by combining biologics expertise, Eisai’s unique Antibody-Drug Conjugate (ADC) technology, proprietary payloads and bispecific antibodies.
*Any ADC employing eribulin as a payload is investigational and has not been approved by regulatory authorities. For more information on HALAVEN® (eribulin mesylate), please see www.halaven.com or contact Eisai’s Medical Information toll-free number: 1-888-274-2378.
Get an in-depth look at EPAT’s proprietary technologies, including: